Abstract
I want to thankDrs Brigo and Olivofor their interest in our recent paper “A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development [1].” I would like to take this the opportunity to respond to the concerns raised in the letter about the randomized controlled trial (RCT) evaluating the use of cannabidiol (CBD) in tuberous sclerosis (TSC), which was extensively discussed in the scoping review [2]. I agree with the general premise of their thoughtful letter that readers must critically assess the evidence supporting the use of add-on CBD for treating TSC-associated seizures before starting routinely prescribing it.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
